Viewing Study NCT01826266


Ignite Creation Date: 2025-12-24 @ 4:12 PM
Ignite Modification Date: 2025-12-27 @ 8:04 AM
Study NCT ID: NCT01826266
Status: COMPLETED
Last Update Posted: 2020-05-28
First Post: 2013-04-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module